SOURCE: Ischemix, Inc.

Ischemix, Inc.

December 09, 2015 17:41 ET

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

New Zealand Is First of a Series of Expected International Patent Grants

MAYNARD, MA--(Marketwired - December 09, 2015) - Ischemix, Inc., a clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems, announced that a patent application covering analogs of its lead compound, CMX-2043, was recently granted approval in New Zealand. This is the first international approval for these analogs, which gained proprietary protection in the US in 2014. This new approval expands the chemical landscape established for CMX-2043 by a patent granted in 2011. Ischemix has been granted 23 international patents to date.

CMX-2043 is currently being investigated in a Phase 2 clinical trial for prevention of contrast-induced acute kidney injury and periprocedural cardiac injury in cardiac catheterization patients. In a previous, successful Phase 2 trial, CMX-2043 demonstrated the ability to significantly reduce cardiac injury in PCI patients.

"This composition of matter and method of use patent further strengthens Ischemix' intellectual property position and advances the field of renal and cardiac cytoprotection in targeting the large, unmet medical needs for prevention of hospital-acquired acute kidney injury, including contrast-induced acute kidney injury, and for periprocedural cardiac injury," said David A. DeWahl, Jr., President and CEO of Ischemix.

Chairman and CSO of Ischemix, Reinier Beeuwkes, commented, "The multi-modal mechanism of action of these compounds provides the opportunity to create effective therapeutics for diseases or conditions that afflict millions of people worldwide."

PCT 610378 entitled "Lipoyl Compounds and Their Use For Treating Ischemic Injury" received approval by the Commissioner of Patents, Trademarks and Designs of New Zealand. This is the first international approval for US Patent No. 8,815,937 B2 entitled with the same name and issued August 26, 2014. This new patent is an extension to US Patent No. 7,928,067 B2 entitled "Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury" issued in April 2011.

About Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems. Ischemix' lead product candidate, CMX-2043, is in a Phase 2 trial for prevention of contrast-induced acute kidney injury and periprocedural cardiac injury. In a previous, successful Phase 2 trial, CMX-2043 demonstrated the ability to reduce cardiac injury in PCI patients. This breakthrough cytoprotective agent activates endogenous pathways of cell survival, enabling vital organs to survive acute challenges that can occur during medical treatment or hospitalization, including invasive cardiovascular procedures, serious infections and agents such as diagnostic contrast media. There are currently no drugs approved for these indications.

Hospital-acquired acute kidney injury (HA-AKI) is associated with increased morbidity, mortality and health care resource consumption. This injury is estimated to afflict approximately three million patients and cause 700,000 deaths worldwide every year. In the US, at least 1.8 million hospitalized patients are diagnosed annually with HA-AKI at a cost of at least $10 billion. The incidence of this injury progressing to renal failure and kidney dialysis has recently been increasing at 10% per year. Ischemix' first target within the overall HA-AKI population is patients at risk of contrast-induced acute kidney injury.

Injury to the heart arising during therapeutic cardiac catheterization (also called PCI or "stenting") and coronary artery bypass surgery (CABG) is a significant problem. There are approximately 600,000 PCIs and 400,000 CABG procedures in the US each year. Up to 16% of PCI patients, depending on the type of procedure being performed, are estimated to sustain a myocardial infarction (MI) during the procedure. As many as 20% of CABG patients suffer short- and long-term complications, including MIs.

Contact Information